Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.4
5.2
Journals
Cancers
Special Issues
Lung Cancer Biomarkers
share announcement

Lung Cancer Biomarkers

A special issue of Cancers (ISSN 2072-6694).

Deadline for manuscript submissions: closed (31 May 2015) | Viewed by 10678

Special Issue Editor

Prof. Dr. Bingliang Fang

E-Mail Website
Guest Editor
Department of Thoracic and Cardiovascular Surgery, Unit 445, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA
Interests: targeted cancer therapy; the mechanisms of action of and/or resistance to anticancer agents; and molecular signatures or biomarkers for predicting treatment response or early diagnosis of lung cancers

Special Issue Information

Dear Colleagues,

This special issue on lung cancer biomarkers invites experts to contribute original research reports and review articles that describe recent studies or progress in biomarkers for lung cancer. Biomarkers play a critical role in translational studies of cancers, including early diagnosis, monitoring recurrences, predicting prognosis and treatment responses to anticancer therapy. Various types of biomarkers have been reported, including genomic DNA (mutations, polymorphisms, and DNA methylations), RNA (mRNA and miRNA), proteins and peptides, metabolites, and circulating tumor cells. Those biomarkers can be detected in primary tumor tissues, blood, sputum and other body fluids. The progress in biomarker development also includes development of new methods or technology to improve the sensitivity and specificity of biomarker detections. Some of the biomarkers have already led to a change of concept practice in the clinical management of lung cancers. For example, analysis on EGFR mutations has dramatically improved the response rate of anti-EGFR therapy by identifying potential responders. Thus, studies on biomarkers will have a significant impact on improving cancer patients’ outcomes.

Potential topics include, but are not limited to:

  • Biomarkers for early diagnosis of lung cancers, such as improving specificity of CT imaging screening
  • Biomarkers for monitoring disease progression or recurrences
  • Biomarkers for predicting treatment responses and personalized therapy
  • Circulating biomarkers
  • Clinical and preclinical evaluations of biomarkers
  • Development of methodology and technology to improve specificity and sensitivity,
  • Multiple biomarker panels

Professor Bingliang Fang
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


Keywords

  • biomarkers
  • early diagnosis
  • personalized therapy
  • monitoring prognosis and recurrence
  • circulating biomarkers
  • target therapy
  • snps

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

232 KiB  
Article
Association between Genetic Variants in DNA Double-Strand Break Repair Pathways and Risk of Radiation Therapy-Induced Pneumonitis and Esophagitis in Non-Small Cell Lung Cancer
by Lina Zhao, Xia Pu, Yuanqing Ye, Charles Lu, Joe Y. Chang and Xifeng Wu
Cancers 2016, 8(2), 23; https://doi.org/10.3390/cancers8020023 - 18 Feb 2016
Cited by 9 | Viewed by 4570
Abstract
Radiation therapy (RT)-induced pneumonitis and esophagitis are commonly developed side effects in non-small cell lung cancer (NSCLC) patients treated with definitive RT. Identifying patients who are at increased risk for these toxicities would help to maximize treatment efficacy while minimizing toxicities. Here, we [...] Read more.
Radiation therapy (RT)-induced pneumonitis and esophagitis are commonly developed side effects in non-small cell lung cancer (NSCLC) patients treated with definitive RT. Identifying patients who are at increased risk for these toxicities would help to maximize treatment efficacy while minimizing toxicities. Here, we systematically investigated single nucleotide polymorphisms (SNPs) within double-strand break (DSB) repair pathway as potential predictive markers for radiation-induced esophagitis and pneumonitis. We genotyped 440 SNPs from 45 genes in DSB repair pathways in 250 stage I–III NSCLC patients who received definitive radiation or chemoradiation therapy, followed by internal validation in 170 additional patients. We found that 11 SNPs for esophagitis and 8 SNPs for pneumonitis showed consistent effects between discovery and validation populations (same direction of OR and reached significance in meta-analysis). Among them, rs7165790 in the BLM gene was significantly associated with decreased risk of esophagitis in both discovery (OR = 0.59, 95% CI: 0.37–0.97, p = 0.037) and validation subgroups (OR = 0.45, 95% CI: 0.22–0.94, p = 0.032). A strong cumulative effect was observed for the top SNPs, and gene-based tests revealed 12 genes significantly associated with esophagitis or pneumonitis. Our results support the notion that genetic variations within DSB repair pathway could influence the risk of developing toxicities following definitive RT in NSCLC. Full article
(This article belongs to the Special Issue Lung Cancer Biomarkers)

Review

Jump to: Research

205 KiB  
Review
Optimizing the Detection of Circulating Markers to Aid in Early Lung Cancer Detection
by Vasudha Murlidhar, Nithya Ramnath, Sunitha Nagrath and Rishindra M. Reddy
Cancers 2016, 8(7), 61; https://doi.org/10.3390/cancers8070061 - 28 Jun 2016
Cited by 11 | Viewed by 5677
Abstract
Improving early detection of lung cancer is critical to improving lung cancer survival. Studies have shown that computerized tomography (CT) screening can reduce mortality from lung cancer, but this involves risks of radiation exposure and can identify non-cancer lung nodules that lead to [...] Read more.
Improving early detection of lung cancer is critical to improving lung cancer survival. Studies have shown that computerized tomography (CT) screening can reduce mortality from lung cancer, but this involves risks of radiation exposure and can identify non-cancer lung nodules that lead to unnecessary interventions for some. There is a critical need to develop alternative, less invasive methods to identify patients who have early-stage lung cancer. The detection of circulating tumor cells (CTCs) are a promising area of research, but current technology is limited by a low yield of CTCs. Alternate studies are investigating circulating nucleic acids and proteins as possible tumor markers. It is critical to develop innovative methods for early lung cancer detection that may include CTCs or other markers that are low-risk and low-cost, yet specific and sensitive, to facilitate improved survival by diagnosing the disease when it is surgically curable. Full article
(This article belongs to the Special Issue Lung Cancer Biomarkers)
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop